drugset / Trial / NCT01867164

A Study to Compare Efficacy and Safety of an Ovule Containing Terconazole, Clindamycin and Fluocinolone Versus an Ovule Containing Metronidazole, Nystatin and Fluocinolone in the Treatment of Secondary Vulvar/ or Vaginal Symptoms of Infectious Vaginitis/ and Infectious Vaginosis

NCT01867164

Phase 3 Completed 160 enrolled Janssen-Cilag, S.A.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this comparative study is to evaluate the efficacy of an ovule with triple active agents (terconazole, clindamycin and fluocinolone) versus another ovule with triple active agents (nystatin, metronidazole and fluocinolone) in the treatment of symptoms caused by the presence of vaginitis (inflammation of the vagina) or bacterial vaginosis (polymicrobial, nonspecific vaginitis associated with positive cultures of Gardnerella vaginalis and other anaerobic organisms and a decrease in lactobacilli).

Timeline

Start
2007-12
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Clindamycin Unknown 100 mg Intravenous
Subject Metronidazole Small molecule 500 mg Intravenous
Subject Nystatin Unknown 100000 ug/ml Intravenous
Subject Terconazole Small molecule 80 mg Intravenous
Background fluocinolone acetonide Small molecule 0.5 mg Intravenous

Indications